Intrabody-based approaches to cancer therapy: status and prospects.
about
Engineering antibody fragments to fold in the absence of disulfide bonds.Engineering antibody fitness and function using membrane-anchored display of correctly folded proteins.Targeting Pyk2 for therapeutic interventionOptimizing recombinant antibodies for intracellular function using hitchhiker-mediated survival selectionThe Pyk2 FERM domain as a target to inhibit glioma migration.Inhibition of protease-inhibitor-resistant hepatitis C virus replicons and infectious virus by intracellular intrabodies.Anti-p19 antibody treatment exacerbates lyme arthritis and enhances borreliacidal activity.Growth signalobody selects functional intrabodies in the mammalian cytoplasm.Antibody technology in proteomics.Therapeutic antibodies: successes, limitations and hopes for the future.Research and development of next generation of antibody-based therapeuticsPharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.EMMPRIN reduction via scFv-M6-1B9 intrabody affects α3β1-integrin and MCT1 functions and results in suppression of progressive phenotype in the colorectal cancer cell line Caco-2.Protein silencing with Phylomers: a new tool for target validation and generating lead biologicals targeting protein interactions.The intrabody targeting of hTERT attenuates the immortality of cancer cells.
P2860
Q33403805-8EE67603-481F-4679-A879-9B4562BD4A0BQ34111656-214A4923-B142-470C-901D-FDC1F160D216Q34146883-1032D3D0-64A2-4540-9992-6E2EBE0E1A25Q34313188-EA1B9877-493C-41FF-943C-E694D56F32EDQ35234199-F219E25F-EDC7-47CC-9A6C-361D202B0AE0Q35565927-BFE8B1E8-A7C5-4E02-B1A3-072C237AC91DQ35783591-7D2DBD5F-47C7-43A0-B79B-18CB4F569F59Q35863642-EF2B674E-A87B-4BCB-AB43-BEB95197715DQ37202448-F37B8B15-866B-4105-868B-5287D9591AACQ37491236-762072E3-F0E6-4BBD-8D80-98575E8E1E6CQ37778732-18D9BCA6-48FC-4084-9F60-B90E316435CAQ38072598-CAC6B022-576C-4C75-B22A-5AFA18FFAA25Q38985433-7BD5F622-C85A-4D6C-B273-3CE7C9476339Q50923792-66D2D45D-58A9-46A0-85BB-97FFC445F9B1Q54719281-0F2E7ABA-1F21-4F7D-BB6B-89C355440640
P2860
Intrabody-based approaches to cancer therapy: status and prospects.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Intrabody-based approaches to cancer therapy: status and prospects.
@ast
Intrabody-based approaches to cancer therapy: status and prospects.
@en
type
label
Intrabody-based approaches to cancer therapy: status and prospects.
@ast
Intrabody-based approaches to cancer therapy: status and prospects.
@en
prefLabel
Intrabody-based approaches to cancer therapy: status and prospects.
@ast
Intrabody-based approaches to cancer therapy: status and prospects.
@en
P1476
Intrabody-based approaches to cancer therapy: status and prospects.
@en
P2093
Brent R Williams
Zhenping Zhu
P304
P356
10.2174/092986706776872899
P577
2006-01-01T00:00:00Z